Lyell Immunopharma, Inc. (LYEL) Social Stream
Lyell Immunopharma Inc (LYEL) Price Targets From Analysts
Use the tables below to see what analysts covering Lyell Immunopharma Inc think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-15 | 3 | $25 | $22 | $24 | $5.36 | 347.76% |
| 2022-01-06 | 3 | $22 | $20 | $20.666 | $5.36 | 285.56% |
| 2022-02-01 | 3 | $22 | $15 | $19 | $5.36 | 254.48% |
| 2022-03-30 | 3 | $20 | $15 | $16.666 | $5.36 | 210.93% |
The Trend in the Analyst Price Target
Over the past 169 days, LYEL's average price target has gone down $7.33.
LYEL reports an average of 107.84% for its upside potential over the past 37 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-08-07 | 2 | 30 | 25 | 27.5 | 15.64 | 75.83% |
| 2021-08-28 | 3 | 30 | 22 | 25.5 | 16.23 | 57.12% |
| 2021-09-11 | 3 | 30 | 22 | 25.5 | 17.95 | 42.06% |
| 2021-09-19 | 3 | 30 | 22 | 25.5 | 11.81 | 115.92% |
| 2022-02-01 | 3 | 22 | 15 | 19.0 | 5.98 | 217.73% |
LYEL Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.17 | 2 | 1 | 0 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
Over the past 28 days, LYEL's average broker recommendation rating improved by 0.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In terms of how Lyell Immunopharma Inc fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is greater than 365.02% of that group.
- In the context of all US stocks, Lyell Immunopharma Inc's number of analysts covering the stock is higher than 44.56% of them.
- In terms of how Lyell Immunopharma Inc fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than 29.12% of that group.
- LYEL has a greater average analyst price target than 83.96% of stocks in the mid market cap category.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Lyell Immunopharma Inc are LMDX, LGND, and LEGN.
Is LYEL a Buy, Hold or Sell? See the POWR Ratings now!